๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation

โœ Scribed by Sandra Joeres; Florian M. A. Heussen; Tobias Treziak; Silvia Bopp; Antonia M. Joussen

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
392 KB
Volume
245
Category
Article
ISSN
0065-6100

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Safety of intranasal Bevacizumab (avasti
Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
โœ Sonia Chen IV; Tom Karnezis; Terence M. Davidson ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB

## Abstract ## Objectives/Hypothesis: Assess for complications of intranasal Bevacizumab application in patients with hereditary hemorrhagic telangiectasia (HHT)โ€associated epistaxis. ## Study Design: Retrospective chart review. ## Methods: In 58 patients presenting with recurrent HHT epistaxi

Efficacy of intranasal bevacizumab (Avas
Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
โœ Tom T. Karnezis; Terence M. Davidson ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB

## Abstract ## Objectives/ Hypothesis: Intranasal Bevacizumab is an effective therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). ## Study Design: Retrospective chart review. ## Methods: In 32 successive patients presenting with recurrent HHT epistaxis 25โ€“100 mg